TY - JOUR
T1 - The blood–brain barrier and beyond
T2 - Nano-based neuropharmacology and the role of extracellular matrix
AU - Henrich-Noack, Petra
AU - Nikitovic, Dragana
AU - Neagu, Monica
AU - Docea, Anca Oana
AU - Engin, Ayse Basak
AU - Gelperina, Svetlana
AU - Shtilman, Michael
AU - Mitsias, Panayiotis
AU - Tzanakakis, George
AU - Gozes, Illana
AU - Tsatsakis, Aristidis
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/4
Y1 - 2019/4
N2 - Restrained drug delivery due to the blood–brain barrier (BBB) considerably limits options for the treatment of brain pathologies. The utilization of nanoparticulate (NP) carriers has been proposed as a solution. The development strategies need to address the important hurdle of NP passage across the BBB as well as the altered cellular up-take due to the pathophysiological changes of the damaged or diseased tissue as well as immunological and toxicological aspects of nanomedicine penetration. This review therefore scopes to: 1) outline the state-of-the art knowledge on BBB passage, 2) address the significant influence of pathological conditions on nanoparticulate drug delivery, and, 3) highlight the largely neglected role of the extracellular matrix (ECM). Interactions of the nanosystem with biological barriers, cells and ECM in the milieu of brain pathologies are critically discussed in order to present a holistic overview of the advances and pits of nanomedicine applications in brain disease.
AB - Restrained drug delivery due to the blood–brain barrier (BBB) considerably limits options for the treatment of brain pathologies. The utilization of nanoparticulate (NP) carriers has been proposed as a solution. The development strategies need to address the important hurdle of NP passage across the BBB as well as the altered cellular up-take due to the pathophysiological changes of the damaged or diseased tissue as well as immunological and toxicological aspects of nanomedicine penetration. This review therefore scopes to: 1) outline the state-of-the art knowledge on BBB passage, 2) address the significant influence of pathological conditions on nanoparticulate drug delivery, and, 3) highlight the largely neglected role of the extracellular matrix (ECM). Interactions of the nanosystem with biological barriers, cells and ECM in the milieu of brain pathologies are critically discussed in order to present a holistic overview of the advances and pits of nanomedicine applications in brain disease.
KW - Blood-brain barrier
KW - Brain pathology
KW - Extracellular matrix
KW - Nanomedicine
KW - Neuropharmacology
UR - https://www.scopus.com/pages/publications/85062488222
U2 - 10.1016/j.nano.2019.01.016
DO - 10.1016/j.nano.2019.01.016
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30759369
AN - SCOPUS:85062488222
SN - 1549-9634
VL - 17
SP - 359
EP - 379
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
ER -